{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:22:06Z","timestamp":1792790526067,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11916-020-00867-7","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T04:53:42Z","timestamp":1594184022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Intravenous Migraine Treatment in Children and Adolescents"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-8076","authenticated-orcid":false,"given":"Klaus","family":"Werner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharoon","family":"Qaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Kabbouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Maconochie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Hershey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"key":"867_CR1","doi-asserted-by":"crossref","unstructured":"Insinga RP, Ng-Mark DS, Hanson ME Costs associated with outpatient, emergency room and inpatient care for migraine in the USA. Cephalgia 2011; 31 (15) :1570\u20131575.","DOI":"10.1177\/0333102411425960"},{"issue":"5","key":"867_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1526-4610.2007.00782.x","volume":"47","author":"L Richer","year":"2007","unstructured":"Richer L, Graham L, Klassen T, Rowe B. Emergency department management of acute migraine in children in Canada: a practice variation study. Headache. 2007;47(5):703\u201310. https:\/\/doi.org\/10.1111\/j.1526-4610.2007.00782.x.","journal-title":"Headache."},{"issue":"1","key":"867_CR3","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1542\/peds.2009-2337","volume":"126","author":"LP Richer","year":"2010","unstructured":"Richer LP, Laycock K, Millar K, Fitzpatrick E, Khangura S, Bhatt M, et al. Treatment of children with migraine in emergency departments: national practice variation study. Pediatrics. 2010;126(1):e150\u20135. https:\/\/doi.org\/10.1542\/peds.2009-2337.","journal-title":"Pediatrics."},{"key":"867_CR4","volume-title":"Pediatric migraine treatment: poor adherence to evidence-based acute medication guidelines","author":"R Nicholson","year":"2015","unstructured":"Nicholson R, Seng E, Smith T, Dummitt B, Yount B. Pediatric migraine treatment: poor adherence to evidence-based acute medication guidelines. 2015."},{"issue":"5","key":"867_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11916-005-0014-7","volume":"9","author":"MA Kabbouche","year":"2005","unstructured":"Kabbouche MA, Linder SL. Management of migraine in children and adolescents in the emergency department and inpatient setting. Curr Pain Headache Rep. 2005;9(5):363\u20137.","journal-title":"Curr Pain Headache Rep"},{"key":"867_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1542\/peds.2014-2432","volume":"135","author":"RG Bachur","year":"2015","unstructured":"Bachur RG, Monuteaux MC, Neuman MI. A comparison of acute treatment regimens for migraine in the emergency department. Pediatrics. 2015;135:232\u20138.","journal-title":"Pediatrics."},{"key":"867_CR7","doi-asserted-by":"crossref","unstructured":"Kabbouche MA, Vockell A-LB, LeCates SL, Powers SW, Hershey AD. Tolerability and effectiveness of prochlorperazine for intractable migraine in children. Pediatrics. 2001;107:e62\u20132.","DOI":"10.1542\/peds.107.4.e62"},{"key":"867_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jemermed.2008.08.012","volume":"39","author":"ED Trottier","year":"2010","unstructured":"Trottier ED, Bailey B, Dauphin-Pierre S, Gravel J. Clinical outcomes of children treated with intravenous prochlorperazine for migraine in a pediatric emergency department. J Emerg Med. 2010;39:166\u201373.","journal-title":"J Emerg Med"},{"key":"867_CR9","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Brousseau DC, Duffy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med. 2004;43:256\u201362 The only double-blind randomized trial for intravenous treatment of pediatric migraine.","DOI":"10.1016\/S0196-0644(03)00716-9"},{"key":"867_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/head.12255","volume":"54","author":"JM Kanis","year":"2014","unstructured":"Kanis JM, Timm NL. Chlorpromazine for the treatment of migraine in a pediatric emergency department. Headache J Head Face Pain. 2014;54:335\u201342.","journal-title":"Headache J Head Face Pain"},{"issue":"5","key":"867_CR11","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1213\/ANE.0b013e31828a4b54","volume":"116","author":"M Bloor","year":"2013","unstructured":"Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. Anesth Analg. 2013;116(5):1063\u201375. https:\/\/doi.org\/10.1213\/ANE.0b013e31828a4b54.","journal-title":"Anesth Analg"},{"issue":"7","key":"867_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11916-017-0631-y","volume":"21","author":"N Karsan","year":"2017","unstructured":"Karsan N, Prabhakar P, Goadsby PJ. Premonitory symptoms of migraine in childhood and adolescence. Curr Pain Headache Rep. 2017;21(7):34. https:\/\/doi.org\/10.1007\/s11916-017-0631-y.","journal-title":"Curr Pain Headache Rep"},{"key":"867_CR13","doi-asserted-by":"publisher","unstructured":"\u2022 Karsan N, Goadsby PJ. Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol. 2018;14(12):699\u2013710. https:\/\/doi.org\/10.1038\/s41582-018-0098-4Excellent review of the premonitory symptoms of migraine and why fluids are appropriate in the management.","DOI":"10.1038\/s41582-018-0098-4"},{"issue":"9","key":"867_CR14","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1111\/head.12443","volume":"54","author":"L Richer","year":"2014","unstructured":"Richer L, Craig W, Rowe B. Randomized controlled trial of treatment expectation and intravenous fluid in pediatric migraine. Headache. 2014;54(9):1496\u2013505. https:\/\/doi.org\/10.1111\/head.12443.","journal-title":"Headache."},{"issue":"3","key":"867_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1046\/j.1526-4610.1996.3603154.x","volume":"36","author":"A Mauskop","year":"1996","unstructured":"Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulfate rapidly alleviates headaches of various types. Headache. 1996;36(3):154\u201360.","journal-title":"Headache"},{"issue":"2","key":"867_CR16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jemermed.2013.08.049","volume":"46","author":"E Gertsch","year":"2014","unstructured":"Gertsch E, Loharuka S, Wolter-Warmerdam K, Tong S, Kempe A, Kedia S. Intravenous magnesium as acute treatment for headaches: a pediatric case series. J Emerg Med. 2014;46(2):308\u201312.","journal-title":"J Emerg Med"},{"issue":"3","key":"867_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1046\/j.1526-4610.2000.00032.x","volume":"40","author":"JC Krusz","year":"2000","unstructured":"Krusz JC, Scott V, Belanger J. Intravenous propofol: unique effectiveness in treating intractable migraine. Headache. 2000;40(3):224\u201330. https:\/\/doi.org\/10.1046\/j.1526-4610.2000.00032.x.","journal-title":"Headache."},{"key":"867_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/00000542-200702000-00043","volume":"106","author":"JA Bloomstone","year":"2007","unstructured":"Bloomstone JA. Propofol: a novel treatment for breaking migraine headache. Anesthesiology. 2007;106:405\u20136.","journal-title":"Anesthesiology"},{"key":"867_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/1471-2377-12-114","volume":"12","author":"H Soleimanpour","year":"2012","unstructured":"Soleimanpour H, Ghafouri RR, Taheraghdam A, et al. Effectiveness of intravenous dexamethasone versus propofol for pain relief in the migraine headache: a prospective double blind randomized clinical trial. BMC Neurol. 2012;12:114.","journal-title":"BMC Neurol"},{"key":"867_CR20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/14737175.2016.1216795","volume":"16","author":"A Dhir","year":"2016","unstructured":"Dhir A. Propofol in the treatment of refractory migraine headaches. Expert Rev Neurother. 2016;16:1007\u201311.","journal-title":"Expert Rev Neurother"},{"key":"867_CR21","first-page":"688","volume":"30","author":"S Robert","year":"2013","unstructured":"Robert S, Ghanayem H. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: propofol for migraine. Emerg Med J. 2013;30:688\u20139.","journal-title":"Emerg Med J"},{"issue":"5","key":"867_CR22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jemermed.2018.01.003","volume":"54","author":"DC Sheridan","year":"2018","unstructured":"Sheridan DC, Hansen ML, Lin AL, Fu R, Meckler GD. Low-dose propofol for pediatric migraine: a prospective, randomized controlled trial. J Emerg Med. 2018;54(5):600\u20136. https:\/\/doi.org\/10.1016\/j.jemermed.2018.01.003.","journal-title":"J Emerg Med"},{"issue":"12","key":"867_CR23","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1097\/PEC.0b013e3182768a6b","volume":"28","author":"DC Sheridan","year":"2012","unstructured":"Sheridan DC, Spiro DM, Nguyen T, Koch TK, Meckler GD. Low-dose propofol for the abortive treatment of pediatric migraine in the emergency department. Pediatr Emerg Care. 2012;28(12):1293\u20136. https:\/\/doi.org\/10.1097\/PEC.0b013e3182768a6b.","journal-title":"Pediatr Emerg Care"},{"key":"867_CR24","doi-asserted-by":"publisher","unstructured":"\u2022 Edvinsson L, Haanes KA, Warfvinge K. Does inflammation have a role in migraine? Nat Rev Neurol. 2019;15(8):483\u201390. https:\/\/doi.org\/10.1038\/s41582-019-0216-yExcellent review about possible role of inflammation in migraine.","DOI":"10.1038\/s41582-019-0216-y"},{"issue":"6","key":"867_CR25","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/head.12835","volume":"56","author":"SL Orr","year":"2016","unstructured":"Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, et al. Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache. 2016;56(6):911\u201340. https:\/\/doi.org\/10.1111\/head.12835.","journal-title":"Headache."},{"issue":"10","key":"867_CR26","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/head.12654","volume":"55","author":"KM Cobb-Pitstick","year":"2015","unstructured":"Cobb-Pitstick KM, Hershey AD, O\u2019Brien HL, Kabbouche MA, LeCates S, White S, et al. Factors influencing migraine recurrence after infusion and inpatient migraine treatment in children and adolescents. Headache. 2015;55(10):1397\u2013403. https:\/\/doi.org\/10.1111\/head.12654.","journal-title":"Headache."},{"issue":"2","key":"867_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/sj.bjp.0705437.PMC1574033","volume":"140","author":"B Schaerlinger","year":"2003","unstructured":"Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol. 2003;140(2):277\u201384. https:\/\/doi.org\/10.1038\/sj.bjp.0705437.PMC1574033.","journal-title":"Br J Pharmacol"},{"key":"867_CR28","doi-asserted-by":"crossref","unstructured":"Sara Frindinger, Christina Szperka. Effectiveness of intravenous dihydroergotamine for pediatric headache: does headache diagnosis matter? Neurology 2018: 90 (15 Supplement).","DOI":"10.1212\/WNL.90.15_supplement.P4.135"},{"issue":"10","key":"867_CR29","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1111\/head.12701","volume":"55","author":"M Kabbouche","year":"2015","unstructured":"Kabbouche M. Pediatric inpatient headache therapy: what is available. Headache. 2015;55(10):1426\u20139.","journal-title":"Headache"},{"key":"867_CR30","doi-asserted-by":"crossref","unstructured":"\u2022 Kabbouche MA, Powers SW, Segers A, et al. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. Headache. 2009;49(1):106\u20139 Excellent evidence for the efficiency of intravenous dihydroergotamine in the treatment of status migraine.","DOI":"10.1111\/j.1526-4610.2008.01293.x"},{"issue":"9","key":"867_CR31","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1212\/WNL.0000000000002406","volume":"86","author":"M Eller","year":"2016","unstructured":"Eller M, Gelfand AA, Riggins NY, et al. Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome. Neurology. 2016;86(9):856\u20139.","journal-title":"Neurology."},{"issue":"1","key":"867_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/1756285615616586","volume":"9","author":"J Kacperski","year":"2016","unstructured":"Kacperski J, Kabbouche MA, O\u2019Brien HL, Weberding JL. The optimal management of headaches in children and adolescents. Ther Adv Neurol Disord. 2016;9(1):53\u201368.","journal-title":"Ther Adv Neurol Disord"},{"key":"867_CR33","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1526-4610.1994.hed3410578.x","volume":"34","author":"SL Linder","year":"1994","unstructured":"Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. Headache J Head Face Pain. 1994;34:578\u201380.","journal-title":"Headache J Head Face Pain"},{"key":"867_CR34","unstructured":"Nickisch J, Merritt G. The Department of Pharmacy, Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. Denver, CO 80218, USA: The Children\u2019s Hospital."},{"issue":"7","key":"867_CR35","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/j.1526-4610.2005.05158.x","volume":"45","author":"PD Reiter","year":"2005","unstructured":"Reiter PD. Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. Headache. 2005;45(7):899\u2013903.","journal-title":"Headache"},{"issue":"1","key":"867_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40263-015-0304-5","volume":"30","author":"Z Cook","year":"2016","unstructured":"Cook Z, et al. Pharmacokinetics and clinical utility of valproic acid administered via continuous infusion. CNS Drugs. 2016;30(1):71\u20137. https:\/\/doi.org\/10.1007\/s40263-015-0304-5.","journal-title":"CNS Drugs"},{"key":"867_CR37","doi-asserted-by":"crossref","unstructured":"\u2022 Zafar, et al. Continuous intravenous valproate as abortive therapy for pediatric status migrainosus. Neurologist. 2018;23(2) Evidence for the efficiency of intravenous valproate in the treatment of status migraine.","DOI":"10.1097\/NRL.0000000000000161"},{"issue":"5","key":"867_CR38","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/head.13298","volume":"58","author":"T Berk","year":"2018","unstructured":"Berk T, Silberstein SD. The use and method of action of intravenous lidocaine and its metabolite in headache disorders. Headache. 2018;58(5):783\u20139. https:\/\/doi.org\/10.1111\/head.13298.","journal-title":"Headache."},{"issue":"8","key":"867_CR39","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/pcc.0000000000001629","volume":"19","author":"MA Ayulo Jr","year":"2018","unstructured":"Ayulo MA Jr, Phillips KE, Tripathi S. Safety and efficacy of IV lidocaine in the treatment of children and adolescents with status migraine. Pediatr Crit Care Med. 2018;19(8):755\u20139. https:\/\/doi.org\/10.1097\/pcc.0000000000001629.","journal-title":"Pediatr Crit Care Med"},{"issue":"11","key":"867_CR40","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/s1474-4422(15)00245-8","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1091\u2013100. https:\/\/doi.org\/10.1016\/s1474-4422(15)00245-8.","journal-title":"Lancet Neurol"},{"issue":"6","key":"867_CR41","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425\u201334. https:\/\/doi.org\/10.1016\/s1474-4422(17)30083-2.","journal-title":"Lancet Neurol"},{"issue":"22","key":"867_CR42","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1709038.","journal-title":"N Engl J Med"},{"issue":"8","key":"867_CR43","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442\u201354. https:\/\/doi.org\/10.1177\/0333102418779543.","journal-title":"Cephalalgia."},{"issue":"19","key":"867_CR44","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. Jama. 2018;319(19):1999\u20132008. https:\/\/doi.org\/10.1001\/jama.2018.4853.","journal-title":"Jama."},{"issue":"9","key":"867_CR45","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1212.","journal-title":"JAMA Neurol"},{"issue":"9","key":"867_CR46","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1177\/0333102419858355","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, et al. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia. 2019;39(9):1075\u201385. https:\/\/doi.org\/10.1177\/0333102419858355.","journal-title":"Cephalalgia."},{"issue":"3","key":"867_CR47","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalgia. 2020;40(3):241\u201354.","journal-title":"Cephalgia"},{"key":"867_CR48","doi-asserted-by":"crossref","unstructured":"Kudrow D, Lipton R, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: results of 2 infusions in the phase 3 PROMISE-2 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy\u20132) Trial (P2.10 006). Neurology. 2019;92(15).","DOI":"10.1212\/WNL.92.15_supplement.P2.10-006"},{"key":"867_CR49","doi-asserted-by":"publisher","unstructured":"\u2022 Nelson GR, Bale JF, Kerr LM. Outcome and cost of inpatient hospitalization for intravenous dihydroergotamine treatment of refractory pediatric headache. Pediatr Neurol. 2017;66:76\u201381. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2016.09.009This reference highlights the importance of costs related to standard of care, i.e., DHE.","DOI":"10.1016\/j.pediatrneurol.2016.09.009"}],"updated-by":[{"DOI":"10.1007\/s11916-020-00888-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000}}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-020-00867-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-020-00867-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-020-00867-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T13:43:45Z","timestamp":1723211025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-020-00867-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["867"],"URL":"https:\/\/doi.org\/10.1007\/s11916-020-00867-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11916-020-00888-2","asserted-by":"object"}]},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]},"assertion":[{"value":"8 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original publication of this article unfortunately contained the incorrect version of the manuscript. The original article has been corrected.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"<b>Klaus Werner<\/b>No conflict of interest<b>Sharron Qaiser<\/b>No conflict of interest<b>Marielle Kabbouche<\/b>CGRP AbAlder\/Lundbeck\u2014site PI; payment to CCHMCLilly\u2014site PI; payment to CCHMCTopiramateSupernus\u2014site PI; payment to CCHMC<b>Beverly Murphy<\/b>No conflict of interest<b>Ian Maconochie<\/b>No conflict of interest<b>Andrew D. Hershey<\/b>CGRP AbAmgen\u2014advisor to study, site PI; payment to CHMCAlder\/Lundbeck\u2014advisor to study; payment to CCHMCLilly\u2014advisor to both CGRP and Ditan studies; payment to CCHMCTeva\u2014advisor to study, not sure about site PI I am international PI for protocols; payment to CCHMCCGRP antagonistAllergan\u2014advisor to study; payment to CCHMCBiohaven\u2014advisor to study; payment to CCHMCTopiramateUpsherSmith\u2014advisor to study, site PI; mixed payment\u2014some to CCHMC, some to me personallySupernus\u2014advisor to study; payment to CCHMCDeviceElectrocore\u2014advisor to study, no paymentTheranica\u2014advisor to study, I am both site PI and international PI; payment to CCHMC","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"45"}}